Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial.
- 2020-07
- RCT · n = 443
- The Lancet Gastroenterology & Hepatology 5(7)
- V. Andresen
- J. Gschossmann
- P. Layer
- PubMed: 32277872
- DOI: 10.1016/S2468-1253(20)30056-X
- High evidence
- Large Human Trial
- Highly Cited
- Rigorous Journal
No serious adverse events occurred in the B bifidum HI-MIMBb75 group; seven adverse events suspected to be related to the study product were reported in the B bifidum HI-MIMBb75 group as were eight in the placebo group. No deaths were reported in this study.
- Effect
- Beneficial
- Effect size
- Large